Amantadine
| Evidence Level: L5 | Predicted Indications: 4 |
Table of Contents
- Amantadine
- Pharmacist Assessment Report
- Amantadine: NMDA receptor antagonist and dopaminergic modulator → Rasmussen subacute encephalitis
- One-Sentence Summary
- Quick Overview
- Why is This Prediction Reasonable?
- Clinical Trial Evidence
- Literature Evidence
- Australia Market Information
- Safety Considerations
- Conclusion and Next Steps
- Disclaimer
Amantadine: NMDA receptor antagonist and dopaminergic modulator → Rasmussen subacute encephalitis
One-Sentence Summary
Amantadine is an oral medicine marketed in Australia as a 100 mg capsule. The TxGNN model predicts it may be relevant to Rasmussen subacute encephalitis with a score of 0.9948. No clinical trials or publications were supplied for this disease, so the prediction rests on the model alone.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Not recorded in the local data |
| Predicted New Indication | Rasmussen subacute encephalitis |
| TxGNN Prediction Score | 0.9948 |
| Evidence Level | L5 |
| Australia Market Status | Listed on the PBS Schedule (1 of 1 items) – TGA (ARTG) registration status is not included in this data |
| Number of PBS Items | 1 (valid: 1) |
| Recommended Decision | Hold |
Why is This Prediction Reasonable?
Detailed mechanism of action data are not available in the data compiled for this report. Amantadine is generally understood to antagonise NMDA receptors and modulate dopaminergic signalling.
Rasmussen encephalitis is a rare, severe, drug-resistant form of epilepsy. Glutamate receptor-mediated excitotoxicity and autoimmune mechanisms have been proposed as contributors. A link to NMDA antagonism is therefore plausible, but it is unverified. No clinical support for amantadine in this condition was found in the data compiled, and the prediction should be treated as a hypothesis only.
Clinical Trial Evidence
Currently no related clinical trials registered.
Literature Evidence
Currently no related literature available.
Australia Market Information
| ARTG Number | Product Name | Dosage Form | Approved Indication |
|---|---|---|---|
| ARTG 14486K | AMANTAMED | Capsule containing amantadine hydrochloride 100 mg | Not recorded in the local data |
Safety Considerations
- Drug Interactions: 93 interactions were identified in the interaction databases. Notable examples:
- Major: bupropion.
- Moderate: anticholinergic agents (atropine, clidinium, dicyclomine, glycopyrronium, hyoscyamine, mepenzolate, methscopolamine, propantheline, scopolamine, trospium), metoclopramide, polyethylene glycol (3350 with electrolytes), picosulfuric acid and sodium sulfate.
- Interactions with calcitriol, pantoprazole, glimepiride, doxycycline and metformin are recorded without a severity grade.
Label warnings and contraindications were not available. Please refer to the TGA-approved Product Information (PI) for full safety information.
Conclusion and Next Steps
Decision: Hold
Rationale: The prediction has a high model score but no supporting trials or publications for Rasmussen subacute encephalitis, so the evidence level is L5. The suggested NMDA-related link is plausible but unverified.
To proceed, the following is needed:
- Mechanism of action data and a documented rationale linking amantadine to Rasmussen encephalitis
- A structured literature search for case reports or preclinical studies in this disease
- TGA Product Information warnings and contraindications for a safety review
- Assessment of suitability for a rare paediatric-onset population, including dosing and renal function considerations
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.